Diabetes

Patients with rheumatoid arthritis or osteoarthritis and comorbid adult-onset type 2 diabetes have a clinical profile of severe diabetes with poor glycemic control, researchers report.

A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.

Adding the SGLT2 inhibitor empagliflozin to standard treatment significantly improves left ventricular remodeling among patients with heart failure and reduced ejection fraction but without diabetes, shows a randomized controlled trial.

A systematic review and meta-analysis highlights a potential increase in the likelihood of achieving type 2 diabetes remission on a low- or very-low-carbohydrate diet, but based on evidence of moderate or low quality.

Researchers find partial restoration of brain responses to hypoglycemia in people with type 1 diabetes who recover hypoglycemia awareness during a multifactorial intervention.

SGLT2 inhibitors are associated with lower rates of heart failure hospitalization, all-cause mortality, and hypoglycemia, but higher rates of diabetic ketoacidosis, when compared with DPP-4 inhibitors in older adults with type 2 diabetes, suggests a Canadian study.

Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

Ghrelin is the only appetite-related hormone that predicted weight regain among the participants of the DiRECT trial, say the researchers.

Adolescents with type 1 diabetes who are obese have a cardiorenal risk profile similar to that of their peers with type 2 diabetes, say researchers.

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

Researchers have detected moderate or severe liver fibrosis in around one in six people with type 2 diabetes.

Increased BMI and insulin resistance are important predictors of diabetic ketoacidosis risk among people with type 1 diabetes using SGLT2 inhibitors, say the authors of a meta-analysis and meta-regression.

Any amount of residual C-peptide is protective against some type 1 diabetes complications, show findings from a large, population-based study.

The use of continuous glucose monitoring does not increase time in range in young children with type 1 diabetes, but may improve other glycemic indices, researchers report.

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

The risk for fatal or critical care unit-treated COVID-19 varies among people with diabetes and can be reasonably well predicted by their clinical history, UK study findings indicate.

A large number of people diagnosed with type 2 diabetes achieve intermediate or even normal glucose levels within the following few years, with regression to the mean accounting for more than half of these remissions, research suggests.

A randomized trial indicates that testosterone treatment among men with prediabetes or newly diagnosed type 2 diabetes significantly reduces the risk for them having type 2 diabetes 2 years later.

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.